Pure Global
NCT06359509

Study of SYS6020 in BCMA-positive Multiple Myeloma

A Phase І Study of BCMA-targeted Chimeric Antigen Receptor T Cell (SYS6020) Injection in Relapsed or Refractory Multiple Myeloma
Wuhan Union Hospital, China·Phase 1·ClinicalTrials.gov·biologicalNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Multiple Myeloma
Drug/Device/Intervention
BCMA Targeted CAR T-cells
Study type
Interventional
Intervention type
biological
Sponsor & location
Primary sponsor
Wuhan Union Hospital, China
Timeline & enrollment
Phase
Phase 1
Start date
Apr 01, 2024
End date
May 01, 2032
Enrollment
10 participants
Primary outcome

Incidence of adverse events (AEs),Dose limiting toxicities (DLTs)

Summary

This is a multi-center, phase I trial that studies the efficacy and recommended dose of BCMA
 CART cells in treating patients with BCMA-positive multiple myeloma (MM) that have not
 respond or relapsed after chemotherapy. B-cell maturation antigen (BCMA), a cell surface
 protein expressed on malignant plasma cell, has emerged as a very selective antigen to be
 targeted in novel immunotherapy for MM.

ICD-10 classifications
Multiple myelomaMultiple myeloma and malignant plasma cell neoplasmsOther myeloid leukaemiaMyeloid leukaemiaOther myelodysplastic syndromes
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06359509
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06359509 through Pure Global AI's free database. This Phase 1 trial is sponsored by Wuhan Union Hospital, China and is currently Not yet recruiting. The study focuses on Multiple Myeloma. Target enrollment is 10 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.